Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel
NASDAQ:BBLG

Bone Biologics Q2 2025 Earnings Report

Bone Biologics logo
$0.88 -0.05 (-5.67%)
As of 03:59 PM Eastern
ProfileEarnings HistoryForecast

Bone Biologics EPS Results

Actual EPS
-$1.33
Consensus EPS
-$0.58
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A

Bone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bone Biologics Announcement Details

Quarter
Q2 2025
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bone Biologics' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

Bone Biologics Earnings Headlines

Bone Biologics (BBLG) Projected to Release Earnings on Thursday
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943860
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332071/0/en/bone-biologics-issues-mid-year-shareholder-update-highlighting-progress-across-2026-priorities.html
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
August 10 at 1:00 AM  |  Stansberry Research (Ad)
BBLG Secures Financing for Critical Trials
July 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/bblg-secures-financing-critical-trials-121500504.html
BONE BIOLOGICS CORPORATION: Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
July 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68970596-bone-biologics-corporation-bone-biologics-announces-up-to-dollar-9-0-million-private-placement-priced-at-the-market-under-nasdaq-rules-399.htm
Bone Biologics enters into definitive agreement for $3.0M private placement
July 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/bone-biologics-enters-into-definitive-agreement-for-30m-private-placement/ar-AA27snJB
See More Bone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email.

About Bone Biologics

Bone Biologics (NASDAQ:BBLG), Inc. (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects. Early-stage clinical studies and preclinical investigations are underway to assess safety, tolerability and preliminary efficacy in these high-need segments. The company collaborates with leading orthopedic surgeons and academic centers to design protocols and gather real-world insights that may inform future pivotal trials.

Founded in the late 2010s and headquartered in New Jersey, Bone Biologics has assembled a leadership team with extensive experience in regenerative medicine, cell therapy manufacturing and orthopedic clinical development. The company maintains partnerships with contract development and manufacturing organizations to scale its cell production processes, while engaging regulatory consultants to support filings with health authorities. As a dedicated cell therapy innovator, Bone Biologics aims to address significant unmet needs in bone repair and establish new standards for patient outcomes in orthopedic care.

View Bone Biologics Profile
Earnings Tools